Effects of glimepiride and glibenclamide on carotid atherosclerosis in type 2 diabetic patients

Diabetes Res Clin Pract. 2011 Apr;92(1):e20-2. doi: 10.1016/j.diabres.2010.12.023. Epub 2011 Jan 22.

Abstract

We performed a 3-year observation study of type 2 diabetic patients treated with glibenclamide or glimepiride and found that the annual progression of the maximum carotid intima-media thickness was significantly attenuated in the subjects treated with glimepiride (n=20) as compared with those treated with glibenclamide (n=20) (-0.044±0.171 mm/year vs. 0.077±0.203 mm/year, p=0.0474).

MeSH terms

  • Aged
  • Carotid Artery Diseases / drug therapy*
  • Carotid Artery Diseases / physiopathology*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / physiopathology*
  • Female
  • Glyburide / therapeutic use*
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Male
  • Middle Aged
  • Sulfonylurea Compounds / therapeutic use*
  • Treatment Outcome

Substances

  • Hypoglycemic Agents
  • Sulfonylurea Compounds
  • glimepiride
  • Glyburide